Experienced in Clear Cell Sarcoma

Albiruni A. Razak

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Clear Cell Sarcoma
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Albiruni Razak practices in Toronto, Canada. Razak is rated as an Experienced expert by MediFind in the treatment of Clear Cell Sarcoma. Their top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Head and Neck Squamous Cell Carcinoma (HNSCC), Osteotomy, and Orchiectomy.

Their clinical research consists of co-authoring 80 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have participated in 1 clinical trial in the study of Clear Cell Sarcoma.

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Enrollment Status: Recruiting
Publish Date: December 04, 2024
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drug: Talimogene Laherparepvec
Study Phase: Phase 2
A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas
A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: KPT-9274, Niacin ER, Nivolumab
Study Phase: Phase 1
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms
Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2024
Intervention Type: Drug
Study Phase: Not Applicable
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 2
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drug: Tegavivint
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)
A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Drug
Study Drugs: Selinexor, Doxorubicin
Study Phase: Phase 1
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumorGraft) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumorGraft) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
Enrollment Status: Terminated
Publish Date: October 06, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 15 Less Clinical Trials

80 Total Publications

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Razak's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile